Miravant Plans Photrex Confirmatory Macular Degeneration Trial
This article was originally published in The Pink Sheet Daily
The trial, to be conducted under a special protocol assessment with FDA, will be one year with another year for confirmatory results. Agency's September 2004 "approvable" letter for the photodynamic therapy requested an additional study. Miravant is also planning combination studies with other age-related macular degeneration agents.
You may also be interested in...
The ophthalmic agent clears FDA under priority review procedures; "It is for all neovascular" age-related macular degeneration, Eyetech COO says. Company expects Macugen will receive broad coverage under Medicare Part B.
FDA needs further confirmation before granting full approval to the photosensitive drug/photodynamic therapy combination, Miravant says. The firm is seeking approval for both predominantly and minimally classic AMD.
A new analysis from BIO, Informa Pharma Intelligence and QLS looks at clinical drug development activity from the past decade, looking at the most (and least) successful areas. Infographic depicts key trends and details.